JONES DALE E
Known title: DirectorCIK: 0001261562
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Hims & Hers news mentioned in broader market context. Recent coverage from Yahoo discusses reasons to retain Hims & Hers stock, which shares the digital health sector with Outset Medical. While the article focuses on a different company, it highlights ongoing investor interest in the broader telehealth and digital medicine space. Outset Medical remains a high-beta stock with significant volatility, as seen in its wide 52-week range.
Transaction History
| ROL | ▲ Buy | Grant | 2,692 | $0 | 4/28/2026 | View on chart |
| ROL | ▲ Buy | Grant | 2,695 | $0 | 4/22/2025 | View on chart |
| OM | ▲ Buy | Grant | 25,000 | $0 | 5/29/2024 | View on chart |
| ROL | ▲ Buy | Grant | 2,228 | $0 | 4/26/2024 | View on chart |
| OM | ▲ Buy | Grant | 7,681 | $0 | 5/31/2023 | View on chart |
| OM | ▲ Buy | Grant | 6,880 | $0 | 5/31/2022 | View on chart |
| OM | ▲ Buy | Grant | 6,357 | $0 | 4/21/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
UBS and JPMorgan Cut Rollins Price Targets Ahead of Earnings
Rollins is set to report its third-quarter earnings next week, drawing attention from investors. UBS and JP Morgan recently lowered their price targets to $36 and $35, respectively, while maintaining neutral ratings. These adjustments come as the stock has fallen significantly from its 52-week high, prompting some analysts to question if the current valuation offers value despite the recent downgrades.
UBS and JPMorgan Cut Rollins Price Targets Ahead of Earnings. Rollins is set to report its third-quarter earnings next week, drawing attention from investors. UBS and JP Morgan recently lowered their price targets to $36 and $35, respectively, while maintaining neutral ratings. These adjustments come as the stock has fallen significantly from its 52-week high, prompting some analysts to question if the current valuation offers value despite the recent downgrades.